Development of hepatocellular carcinoma in patients with chronic hepatitis C who had sustained viral response following direct-acting antiviral therapy

Creative Commons License

Ebik B., Aygan M., Tuncel E. T., Kacmaz H., Ekin N., ARPA M., ...Daha Fazla

HEPATOLOGY FORUM, cilt.3, sa.3, ss.82-87, 2022 (ESCI) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 3 Sayı: 3
  • Basım Tarihi: 2022
  • Doi Numarası: 10.14744/hf.2022.2022.0016
  • Dergi Adı: HEPATOLOGY FORUM
  • Derginin Tarandığı İndeksler: Emerging Sources Citation Index (ESCI), TR DİZİN (ULAKBİM)
  • Sayfa Sayıları: ss.82-87
  • Anahtar Kelimeler: Chronic Hepatitis C infection, direct-acting antiviral agents, hepatocellular carcinoma, VIROLOGICAL RESPONSE, ADVANCED FIBROSIS, CIRRHOSIS, INTERFERON/RIBAVIRIN, RECURRENCE, OUTCOMES, HCC
  • Recep Tayyip Erdoğan Üniversitesi Adresli: Evet

Özet

Background and Aim: Several studies have suggested that treatment with direct-acting antivirals (DAAs) in patients with chronic hepatitis C virus (HCV) may be associated with an increased risk of developing hepatocellular carcinoma (HCC). We investigated the incidence and risk factors of HCC in HCV patients who achieved a sustained virologic response (SVR) following DAA therapies.